Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: A trial comparing doses of GD2-keyhole limpet hemocyanin Journal Article


Authors: Chapman, P. B.; Morrisey, D.; Panageas, K. S.; Williams, L.; Lewis, J. J.; Israel, R. J.; Hamilton, W. B.; Livingston, P. O.
Article Title: Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: A trial comparing doses of GD2-keyhole limpet hemocyanin
Abstract: Immunization with GMK vaccine (GM2 ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti-GM2 antibodies in close to 100% of patients. We found previously that anti-GD2 antibodies could be induced in some patients using GD2-keyhole limpet hemocyanin + QS-21 (GDK). In this trial, we wished: (a) to determine whether immunization with both GMK and GDK vaccines could induce antibodies against both GM2 and GD2; and (b) to determine the optimal dose of GDK. Thirty-one patients with melanoma or sarcoma who had no evidence of disease after complete surgical resection were immunized with both GMK (30 μg of GM2) and GDK on weeks 1, 2, 3, 4, 12, 24, and 36. Patients were assigned to one of five GDK dose levels (3, 10, 30, 70, or 130 μg of GD2). Anti-GM2 IgM or IgG were induced in 97% of patients. The dose of GDK did not affect the anti-GM2 response, although at the highest GDK dose level, 3 of 7 patients did not make anti-GM2 IgG. GDK was less immunogenic;overall 45% of patients developed either IgM or IgG against GD2. At GDK doses of 30 or 70 μg, 8 of 11 patients (73%) made either IgM or IgG anti-GD2 antibodies. We conclude that both GMK and GDK vaccines can induce antibodies against GM2 and GD2 in a majority of patients and are safe. The optimal dose of GDK appears to be either 30 or 70 μg when administered with GMK vaccine.
Keywords: clinical article; controlled study; clinical trial; drug safety; comparative study; flow cytometry; melanoma; controlled clinical trial; randomized controlled trial; recurrence; dose-response relationship, drug; time factors; sarcoma; immunoglobulin g; cancer vaccines; ganglioside gd2; immunogenicity; antibody response; cancer immunization; immunoblotting; enzyme-linked immunosorbent assay; immunoglobulin g antibody; ganglioside gm2; keyhole limpet hemocyanin; immunoglobulin m antibody; hemocyanin; immunoglobulin m; gangliosides; g(m2) ganglioside; chromatography, thin layer; humans; human; male; female; priority journal; article
Journal Title: Clinical Cancer Research
Volume: 6
Issue: 12
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2000-12-01
Start Page: 4658
End Page: 4662
Language: English
PUBMED: 11156217
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Jonathan J Lewis
    109 Lewis
  2. Paul Chapman
    308 Chapman
  3. Katherine S Panageas
    406 Panageas